Waljee Akbar K, Wiitala Wyndy L, Govani Shail, Stidham Ryan, Saini Sameer, Hou Jason, Feagins Linda A, Khan Nabeel, Good Chester B, Vijan Sandeep, Higgins Peter D R
VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, United States of America.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, United States of America.
PLoS One. 2016 Jun 23;11(6):e0158017. doi: 10.1371/journal.pone.0158017. eCollection 2016.
Corticosteroids are effective for the short-term treatment of inflammatory bowel disease (IBD). Long-term use, however, is associated with significant adverse effects. To define the: (1) frequency and duration of corticosteroid use, (2) frequency of escalation to corticosteroid-sparing therapy, (3) rate of complications related to corticosteroid use, (4) rate of appropriate bone density measurements (dual energy X-ray absorptiometry [DEXA] scans), and (5) factors associated with escalation and DEXA scans.
Retrospective review of Veterans Health Administration (VHA) data from 2002-2010.
Of the 30,456 Veterans with IBD, 32% required at least one course of corticosteroids during the study time period, and 17% of the steroid users had a prolonged course. Among these patients, only 26.2% underwent escalation of therapy. Patients visiting a gastroenterology (GI) physician were significantly more likely to receive corticosteroid-sparing medications. Factors associated with corticosteroid-sparing medications included younger age (OR = 0.96 per year,95%CI:0.95, 0.97), male gender (OR = 2.00,95%CI:1.16,3.46), GI visit during the corticosteroid evaluation period (OR = 8.01,95%CI:5.85,10.95) and the use of continuous corticosteroids vs. intermittent corticosteroids (OR = 2.28,95%CI:1.33,3.90). Rates of complications per 1000 person-years after IBD diagnosis were higher among corticosteroid users (venous thromboembolism [VTE] 9.0%; fragility fracture 2.6%; Infections 54.3) than non-corticosteroid users (VTE 4.9%; fragility fracture 1.9%; Infections 26.9). DEXA scan utilization rates among corticosteroid users were only 7.8%.
Prolonged corticosteroid therapy for the treatment of IBD is common and is associated with significant harm to patients. Patients with prolonged use of corticosteroids for IBD should be referred to gastroenterology early and universal efforts to improve the delivery of high quality care should be undertaken.
皮质类固醇对炎症性肠病(IBD)的短期治疗有效。然而,长期使用会带来显著的不良反应。本研究旨在确定:(1)皮质类固醇的使用频率和持续时间;(2)升级至皮质类固醇节省疗法的频率;(3)与皮质类固醇使用相关的并发症发生率;(4)适当进行骨密度测量(双能X线吸收法[DEXA]扫描)的比例;以及(5)与升级治疗和DEXA扫描相关的因素。
对退伍军人健康管理局(VHA)2002年至2010年的数据进行回顾性分析。
在30456例患有IBD的退伍军人中,32%在研究期间至少需要一个疗程的皮质类固醇治疗,其中17%的皮质类固醇使用者疗程较长。在这些患者中,只有26.2%接受了升级治疗。看胃肠病(GI)科医生的患者更有可能接受皮质类固醇节省药物治疗。与皮质类固醇节省药物相关的因素包括年龄较小(每年OR = 0.96,95%CI:0.95,0.97)、男性(OR = 2.00,95%CI:1.16,3.46)、在皮质类固醇评估期间看GI科(OR = 8.01,95%CI:5.85,10.95)以及使用持续皮质类固醇与间歇皮质类固醇(OR = 2.28,95%CI:1.33,3.90)。IBD诊断后每1000人年的并发症发生率在皮质类固醇使用者中高于非皮质类固醇使用者(静脉血栓栓塞[VTE]9.0%;脆性骨折2.6%;感染54.3)(VTE 4.9%;脆性骨折1.9%;感染26.9)。皮质类固醇使用者中DEXA扫描利用率仅为7.8%。
长期使用皮质类固醇治疗IBD很常见,且对患者有显著危害。IBD长期使用皮质类固醇的患者应尽早转诊至胃肠病科,并应做出全面努力以改善高质量护理的提供。